Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

10/8/24 4:54:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TLPH alert in real time by email

SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors. The summit is being held on October 15-17, 2024.

Event: 2024 Maxim Healthcare Virtual Summit

Date: October 16, 2024

Time: 3:00 PM ET / 12:00 Noon PT

Webcast link: 2024 Maxim Healthcare Virtual Summit

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-in-fireside-chat-at-the-2024-maxim-healthcare-virtual-summit-302270671.html

SOURCE Talphera, Inc.

Get the next $TLPH alert in real time by email

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Chat with this insight

Recent Analyst Ratings for
$TLPH

$TLPH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Talphera with a new price target

$TLPH
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $125,000 worth of shares (213,310 units at $0.59) and was granted 61,000 shares, increasing direct ownership by 149% to 474,769 units (SEC Form 4)

Chief Medical Officer Aslam Shakil bought $6,038 worth of shares (5,695 units at $1.06), increasing direct ownership by 18% to 37,695 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $3,200 worth of shares (5,000 units at $0.64), increasing direct ownership by 2% to 208,066 units (SEC Form 4)

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Chat with this insight

Recent Analyst Ratings for $TLPH

$TLPH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Talphera with a new price target

$TLPH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $125,000 worth of shares (213,310 units at $0.59) and was granted 61,000 shares, increasing direct ownership by 149% to 474,769 units (SEC Form 4)

Chief Medical Officer Aslam Shakil bought $6,038 worth of shares (5,695 units at $1.06), increasing direct ownership by 18% to 37,695 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $3,200 worth of shares (5,000 units at $0.64), increasing direct ownership by 2% to 208,066 units (SEC Form 4)

Recent Analyst Ratings for
$TLPH

$TLPH
Analyst Ratings

$TLPH
Insider Purchases